104 related articles for article (PubMed ID: 16822849)
1. Breaking the one antibody-one target axiom.
Guo F; Das S; Mueller BM; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11009-14. PubMed ID: 16822849
[TBL] [Abstract][Full Text] [Related]
2. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
[TBL] [Abstract][Full Text] [Related]
3. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.
Rader C; Sinha SC; Popkov M; Lerner RA; Barbas CF
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5396-400. PubMed ID: 12702756
[TBL] [Abstract][Full Text] [Related]
4. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
[TBL] [Abstract][Full Text] [Related]
5. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
[TBL] [Abstract][Full Text] [Related]
6. Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro.
Goswami RK; Bajjuri KM; Forsyth JS; Das S; Hassenpflug W; Huang ZZ; Lerner RA; Felding-Habermann B; Sinha SC
Bioconjug Chem; 2011 Aug; 22(8):1535-44. PubMed ID: 21774545
[TBL] [Abstract][Full Text] [Related]
7. Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.
Liu Y; Goswami RK; Liu C; Sinha SC
Mol Pharm; 2015 Jul; 12(7):2544-50. PubMed ID: 26024761
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Abraham S; Guo F; Li LS; Rader C; Liu C; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5584-9. PubMed ID: 17372220
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis.
Felding-Habermann B; Lerner RA; Lillo A; Zhuang S; Weber MR; Arrues S; Gao C; Mao S; Saven A; Janda KD
Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17210-5. PubMed ID: 15563590
[TBL] [Abstract][Full Text] [Related]
10. Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.
Gavrilyuk JI; Wuellner U; Barbas CF
Bioorg Med Chem Lett; 2009 Mar; 19(5):1421-4. PubMed ID: 19181522
[TBL] [Abstract][Full Text] [Related]
11. The Chemistry of Creating Chemically Programmed Antibodies (cPAbs): Site-Specific Bioconjugation of Small Molecules.
Aigbogun OP; Phenix CP; Krol ES; Price EW
Mol Pharm; 2023 Feb; 20(2):853-874. PubMed ID: 36696533
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
13. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
[TBL] [Abstract][Full Text] [Related]
14. Multiple catalytic aldolase antibodies suitable for chemical programming.
Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
[TBL] [Abstract][Full Text] [Related]
15. Functional single-walled carbon nanotubes based on an integrin alpha v beta 3 monoclonal antibody for highly efficient cancer cell targeting.
Ou Z; Wu B; Xing D; Zhou F; Wang H; Tang Y
Nanotechnology; 2009 Mar; 20(10):105102. PubMed ID: 19417509
[TBL] [Abstract][Full Text] [Related]
16. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.
Garcia AG; Nedev H; Bijian K; Su J; Alaoui-Jamali MA; Saragovi HU
Oncogene; 2013 May; 32(20):2527-33. PubMed ID: 22797066
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner.
Vellon L; Menendez JA; Liu H; Lupu R
Differentiation; 2007 Nov; 75(9):819-30. PubMed ID: 17999741
[TBL] [Abstract][Full Text] [Related]
18. ADAM23 negatively modulates alpha(v)beta(3) integrin activation during metastasis.
Verbisck NV; Costa ET; Costa FF; Cavalher FP; Costa MD; Muras A; Paixão VA; Moura R; Granato MF; Ierardi DF; Machado T; Melo F; Ribeiro KB; Cunha IW; Lima VC; Maciel Mdo S; Carvalho AL; Soares FF; Zanata S; Sogayar MC; Chammas R; Camargo AA
Cancer Res; 2009 Jul; 69(13):5546-52. PubMed ID: 19549921
[TBL] [Abstract][Full Text] [Related]
19. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression.
Takayama S; Ishii S; Ikeda T; Masamura S; Doi M; Kitajima M
Anticancer Res; 2005; 25(1A):79-83. PubMed ID: 15816522
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer.
Walser TC; Rifat S; Ma X; Kundu N; Ward C; Goloubeva O; Johnson MG; Medina JC; Collins TL; Fulton AM
Cancer Res; 2006 Aug; 66(15):7701-7. PubMed ID: 16885372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
